The European Pharmaceutical Aerosol Group
 
The European Pharmaceutical Aerosol Group (EPAG) is a voluntary non-profit making consortium of member companies open to "European Pharmaceutical Companies that develop new products for human use utilising the Pulmonary or Nasal route of of delivery".  By sharing of non-confidential information, EPAG's objectives are:
  • To focus on Pharmaceutical issues relevant to Pulmonary and Nasal Delivery products, including clinical aspects as appropriate
     
  • Establish scientifically based best practices
     
  • Provide consensus comment to Industry and Government Agencies to promote safety and quality standards
     
  • To recommend harmonised standards and methodology

Members:
 3M, Almirall Sofotec, AstraZeneca, Bespak Europe Ltd, Boehringer Ingelheim, Chiesi, Clinical Designs Ltd, GlaxoSmithKline, Hovione, Novartis, Pari, Pfizer, PharmaForm, sanofi-aventis, Seigfried Pharma Development, SkyePharma, Teva, Trudell Medical International, Valois, Vectura

EPAG gratefully acknowledges the following companies that have hosted an EPAG meeting: Perlos/Medifiq (06/04), Wilden (06/05), Mikron Assemblies (09/05) and Sagentia (03/08).